Protagonist CEO exercises options, sells 54,700 shares

Protagonist Therapeutics director and CEO Dinesh V. Patel reported option exercises, share sales, and a gift of stock.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Protagonist Therapeutics director and CEO Dinesh V. Patel reported option exercises, share sales, and a gift of stock. On March 24–25, he exercised stock options covering 54,700 shares of Common Stock at an exercise price of $8.58 per share and acquired the same number of shares.

He then sold 54,700 Common Stock shares in open-market transactions at $101.00 per share. On March 23, he made a bona fide gift of 50,000 Common Stock shares to relatives. Following these transactions, Patel directly holds 524,938 shares of Protagonist Therapeutics Common Stock.

Insider Trade Summary

Exercise and Sale: 54,700 shares ($5.06M approx. pre-tax spread)

Exercise and Sale 7 txns

Insider PATEL DINESH V PH D

Role President and CEO

Sold 54,700 shs ($5.52M)

Approx. gross sale proceeds $5.52M

Approx. exercise cost $469K

Approx. pre-tax spread $5.06M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	54,641	$0.00	$0.00
Exercise	Common Stock	54,641	$8.58	$469K
Sale	Common Stock	54,641	$101.00	$5.52M
Exercise	Stock Option (right to buy)	59	$0.00	$0.00
Exercise	Common Stock	59	$8.58	$506.22
Sale	Common Stock	59	$101.00	$6K
Gift	Common Stock	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 524,938 shares (Direct)

Footnotes (3)

F1. This transaction involves a bona fide gift of securities from the Reporting Person to relatives.
F2. Includes an aggregate of 433 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2026.
F3. These stock options are fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did PTGX CEO Dinesh Patel report on this Form 4?

Dinesh V. Patel reported exercising stock options into 54,700 Protagonist Therapeutics shares at $8.58 and selling 54,700 shares at $101.00 per share, plus gifting 50,000 shares to relatives. These actions combined derivative exercises, open-market sales, and a bona fide gift.

How many Protagonist Therapeutics (PTGX) shares did the CEO sell?

The CEO sold 54,700 shares of Protagonist Therapeutics Common Stock in open-market transactions at $101.00 per share. These sales were reported over March 24–25 and followed the exercise of stock options into the same number of shares at an exercise price of $8.58.

What stock options did the PTGX CEO exercise and at what price?

Dinesh V. Patel exercised stock options for 54,700 underlying Protagonist Therapeutics Common Stock shares at an exercise price of $8.58 per share. The filing notes these options were fully vested and the exercises occurred on March 24 and March 25 before the related share sales.

Did the Protagonist Therapeutics CEO make any stock gifts in this filing?

Yes. The Form 4 shows a bona fide gift of 50,000 Protagonist Therapeutics Common Stock shares on March 23. A footnote explains this transfer was a gift of securities from Dinesh V. Patel to relatives, rather than an open-market sale transaction.

How many Protagonist Therapeutics (PTGX) shares does the CEO hold after these transactions?

After the reported option exercises, sales, and the gift, Dinesh V. Patel directly holds 524,938 shares of Protagonist Therapeutics Common Stock. The filing also notes that this amount includes 433 shares acquired under the company’s 2016 Employee Stock Purchase Plan on March 9, 2026.

Were any stock option holdings left after the PTGX CEO’s exercises?

The filing shows stock options for 54,700 shares were exercised, and the derivative holdings table is empty afterward. That indicates no remaining reportable stock options from this grant following the March 24–25 exercises, which had an exercise price of $8.58 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/25/2026 - 07:23 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATEL DINESH V PH D

(Last)

(First)

(Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK

CALIFORNIA

94560-1160

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/23/2026		G⁽¹⁾		50,000	D	$0.00	524,938⁽²⁾	D
Common Stock	03/24/2026		M		59	A	$8.58	524,997	D
Common Stock	03/24/2026		S		59	D	$101	524,938	D
Common Stock	03/25/2026		M		54,641	A	$8.58	579,579	D
Common Stock	03/25/2026		S		54,641	D	$101	524,938	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$8.58	03/24/2026		M			59	⁽³⁾	08/14/2028	Common Stock	59	$0.00	54,641	D
Stock Option (right to buy)	$8.58	03/25/2026		M			54,641	⁽³⁾	08/14/2028	Common Stock	54,641	$0.00	0	D

Explanation of Responses:

1. This transaction involves a bona fide gift of securities from the Reporting Person to relatives.

2. Includes an aggregate of 433 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2026.

3. These stock options are fully vested.

	/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR